Transthyretin Amyloidosis Treatment Market Size, Share, Trends, Growth Outlook

Transthyretin Amyloidosis Treatment Market is estimated to increase at a growth rate of 8.2% CAGR over the forecast period from 2024 to 2030.

The global Transthyretin Amyloidosis Treatment Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Treatment (Targeted Therapy, Supportive Therapy, Pipeline Therapy), By Type (ATTR-PN, ATTR-CM), By Disease (Hereditary Transthyretin Amyloidosis, Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies).

An introduction to Transthyretin Amyloidosis Treatment Market in 2024

Addressing a rare and progressive disease, the Transthyretin Amyloidosis Treatment Market offers targeted therapies and disease-modifying interventions for transthyretin amyloidosis, a rare genetic disorder characterized by the abnormal deposition of amyloid fibrils in various tissues and organs, leading to multisystem dysfunction, neuropathy, and cardiomyopathy. Transthyretin amyloidosis can manifest as hereditary ATTR amyloidosis (hATTR) or wild-type ATTR amyloidosis (wtATTR), presenting with a range of clinical symptoms and complications that impact quality of life and survival. Treatment options for transthyretin amyloidosis include pharmacologic agents that stabilize or reduce the production of abnormal transthyretin proteins, liver transplantation to replace the mutant transthyretin gene, and emerging gene-silencing therapies aimed at suppressing transthyretin expression. This market serves geneticists, neurologists, cardiologists, and healthcare providers specializing in amyloidosis diagnosis and management, offered by pharmaceutical companies, biotechnology firms, and academic medical centers conducting clinical trials and research in transthyretin amyloidosis. With the increasing recognition of transthyretin amyloidosis, advances in genetic testing, and the development of targeted therapies, the Transthyretin Amyloidosis Treatment Market continues to evolve. As researchers uncover new insights into disease pathogenesis, identify novel therapeutic targets, and advance precision medicine approaches in transthyretin amyloidosis, the market holds promise for improving patient outcomes, delaying disease progression, and ultimately, finding a cure for this debilitating condition.

Transthyretin Amyloidosis Treatment Market Trend: Advancements in Disease Understanding and Treatment Approaches

One prominent trend in the Transthyretin Amyloidosis Treatment market is the ongoing advancements in understanding the disease mechanisms and the development of novel treatment approaches. Transthyretin amyloidosis, a rare and progressive disease characterized by the deposition of abnormal protein aggregates in various organs, poses significant challenges in diagnosis and management. However, recent research efforts have led to a deeper understanding of the pathophysiology of the disease, including the role of transthyretin protein misfolding and aggregation in tissue damage. Additionally, there has been progress in the development of targeted therapies such as RNA interference (RNAi) agents, monoclonal antibodies, and small molecule inhibitors that aim to disrupt the production or deposition of abnormal transthyretin proteins. This trend towards advancements in disease understanding and treatment approaches underscores the ongoing efforts to address the unmet medical needs of patients with transthyretin amyloidosis, driving innovation and growth in the treatment market.

Transthyretin Amyloidosis Treatment Market Driver: Rising Awareness and Diagnosis Rates of Transthyretin Amyloidosis

A significant driver in the Transthyretin Amyloidosis Treatment market is the rising awareness and diagnosis rates of transthyretin amyloidosis among healthcare providers and patients. Previously considered a rare and underdiagnosed condition, transthyretin amyloidosis is increasingly recognized as a cause of cardiomyopathy, neuropathy, and other systemic manifestations, particularly among elderly populations. With advancements in diagnostic techniques such as genetic testing, imaging modalities, and biomarker assays, there has been improved detection and diagnosis of transthyretin amyloidosis, leading to earlier intervention and treatment initiation. The growing awareness of the disease among healthcare professionals and the public, coupled with efforts to implement screening protocols and educate clinicians, drives the demand for effective treatment options and drives market growth in the Transthyretin Amyloidosis Treatment segment.

Transthyretin Amyloidosis Treatment Market Opportunity: Expansion of Therapeutic Options and Personalized Medicine

An emerging opportunity in the Transthyretin Amyloidosis Treatment market lies in the expansion of therapeutic options and personalized medicine approaches for patient management. With the introduction of novel therapies targeting different stages of transthyretin amyloidosis pathogenesis, there is potential to improve treatment outcomes, slow disease progression, and enhance patient quality of life. Additionally, opportunities exist to implement personalized medicine approaches that tailor treatment strategies based on individual patient characteristics such as genotype, phenotype, disease severity, and comorbidities. By leveraging biomarkers, genetic testing, and other diagnostic tools to stratify patients and guide treatment decisions, healthcare providers can optimize therapeutic efficacy, minimize treatment-related adverse events, and improve long-term outcomes in patients with transthyretin amyloidosis. This expansion of therapeutic options and personalized medicine approaches presents opportunities for market growth, innovation, and improved patient care in the Transthyretin Amyloidosis Treatment market.

Transthyretin Amyloidosis Treatment Market Market Segmentation

By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Transthyretin Amyloidosis Treatment Market Companies

Acrotech Biopharma
Alnylam Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca
BridgeBio Pharma Inc
Bristol-Myers Squibb Company
Ionis Pharmaceuticals Inc
Johnson & Johnson Services Inc
Pfizer Inc
Prothena
SOM Biotech

Reasons to Buy the Transthyretin Amyloidosis Treatment Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Transthyretin Amyloidosis Treatment Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Transthyretin Amyloidosis Treatment Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Transthyretin Amyloidosis Treatment Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Transthyretin Amyloidosis Treatment Market Size Outlook, $ Million, 2021 to 2030
3.2 Transthyretin Amyloidosis Treatment Market Outlook by Type, $ Million, 2021 to 2030
3.3 Transthyretin Amyloidosis Treatment Market Outlook by Product, $ Million, 2021 to 2030
3.4 Transthyretin Amyloidosis Treatment Market Outlook by Application, $ Million, 2021 to 2030
3.5 Transthyretin Amyloidosis Treatment Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Transthyretin Amyloidosis Treatment Industry
4.2 Key Market Trends in Transthyretin Amyloidosis Treatment Industry
4.3 Potential Opportunities in Transthyretin Amyloidosis Treatment Industry
4.4 Key Challenges in Transthyretin Amyloidosis Treatment Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Transthyretin Amyloidosis Treatment Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Transthyretin Amyloidosis Treatment Market Outlook by Segments
7.1 Transthyretin Amyloidosis Treatment Market Outlook by Segments, $ Million, 2021- 2030
By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

8 North America Transthyretin Amyloidosis Treatment Market Analysis and Outlook To 2030
8.1 Introduction to North America Transthyretin Amyloidosis Treatment Markets in 2024
8.2 North America Transthyretin Amyloidosis Treatment Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Transthyretin Amyloidosis Treatment Market size Outlook by Segments, 2021-2030
By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

9 Europe Transthyretin Amyloidosis Treatment Market Analysis and Outlook To 2030
9.1 Introduction to Europe Transthyretin Amyloidosis Treatment Markets in 2024
9.2 Europe Transthyretin Amyloidosis Treatment Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Transthyretin Amyloidosis Treatment Market Size Outlook by Segments, 2021-2030
By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

10 Asia Pacific Transthyretin Amyloidosis Treatment Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Transthyretin Amyloidosis Treatment Markets in 2024
10.2 Asia Pacific Transthyretin Amyloidosis Treatment Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Transthyretin Amyloidosis Treatment Market size Outlook by Segments, 2021-2030
By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

11 South America Transthyretin Amyloidosis Treatment Market Analysis and Outlook To 2030
11.1 Introduction to South America Transthyretin Amyloidosis Treatment Markets in 2024
11.2 South America Transthyretin Amyloidosis Treatment Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Transthyretin Amyloidosis Treatment Market size Outlook by Segments, 2021-2030
By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

12 Middle East and Africa Transthyretin Amyloidosis Treatment Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Transthyretin Amyloidosis Treatment Markets in 2024
12.2 Middle East and Africa Transthyretin Amyloidosis Treatment Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Transthyretin Amyloidosis Treatment Market size Outlook by Segments, 2021-2030
By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Acrotech Biopharma
Alnylam Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca
BridgeBio Pharma Inc
Bristol-Myers Squibb Company
Ionis Pharmaceuticals Inc
Johnson & Johnson Services Inc
Pfizer Inc
Prothena
SOM Biotech
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Treatment Therapy
Targeted Therapy
-Onpattro
-Inotersen
-Vyndaqel/Vyndamax
Supportive Therapy
Pipeline Therapy
By Type
ATTR-PN
ATTR-CM
By Disease Type
Hereditary Transthyretin Amyloidosis
-Polyneuropathy
-Cardiomyopathy
-Mixed Type
Wild Type Amyloidosis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies